 Connection
Ashley Frazer-Abel to Oligonucleotides, Antisense
This is a "connection" page, showing publications Ashley Frazer-Abel has written about Oligonucleotides, Antisense.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.541 |
|
|
|
-
Barbour SJ, Hladunewich MA, McCaleb ML, Robson R, Barrett TD, Yin L, Frazer-Abel A, Garg JP, Geary R, Schneider E, Brice GT. A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy. Kidney Int. 2026 Mar; 109(3):592-601.
Score: 0.226
-
McCaleb ML, Hughes SG, Grossman TR, Frazer-Abel A, Jung B, Yin L, Henry SP, Monia BP, Schneider E, Geary R, Brice GT. Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen. Immunobiology. 2025 03; 230(2):152876.
Score: 0.212
-
Shen L, Frazer-Abel A, Reynolds PR, Giclas PC, Chappell A, Pangburn MK, Younis H, Henry SP. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans. J Pharmacol Exp Ther. 2014 Dec; 351(3):709-17.
Score: 0.104
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|